Biogen Inc

Biogen Inc

BIIB · NASDAQ · Healthcare / Drug Manufacturers - General

253.40USD+2.92 (+1.17%)

Price History

Full chart

Market Stats

Previous Close250.48
Open250.58
Day Range249.52 – 255.04
52-Week Range154.20 – 261.00
Volume1.03M
Market Cap36.71B
P/E (TTM)107.51
Forward P/E16.08
EPS2.31
Dividend Yield0.00%
Beta0.09
50-Day Avg230.01
200-Day Avg203.18

About

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - General
  • CEOMr. Christopher A. Viehbacher
  • Employees7.50K
  • Headquarters225 Binney Street, Cambridge, MA, United States, 02142, USA
  • Websitehttps://www.biogen.com

Leadership

  • Mr. Christopher A. ViehbacherPresident, CEO & Director · b. 1961
  • Ms. Robin C. KramerExecutive VP & CFO · b. 1966
  • Ms. Nicole MurphyExecutive VP and Head of Pharmaceutical Operations & Technology · b. 1973
  • Dr. Priya Singhal M.D., M.P.H.Executive VP & Head of Development · b. 1968
  • Mr. Sean GodboutVP, Chief Accounting Officer & Global Corporate Controller · b. 1974
  • Mr. Guy HadariChief Information Officer
  • Mr. Tim Power M.B.A., Ph.D.Head of Investor Relations
  • Mr. Michael John Parini J.D.Chief Legal Officer · b. 1974
  • Ms. Natacha GassenbachChief Communication Officer & Head of Corporate Affairs
  • Mr. Adam Keeney Ph.D.Executive VP & Head of Corporate Development · b. 1977

Financials

Income Statement

Currency: USD1986-12-311987-12-311988-12-311989-12-311990-12-311991-12-311992-12-311993-12-311994-12-311995-12-311996-12-311997-12-311998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue6.40M8.60M20.60M28.50M50.10M61.40M123.70M136.40M156.34M151.69M277.09M434.04M557.59M794.43M925.66M1.04B404.22M186.13M1.60B1.71B2.68B3.17B4.10B4.38B4.72B5.05B5.51B6.93B9.70B10.76B11.45B12.27B13.45B14.38B13.44B10.98B10.17B9.84B9.68B9.81B
Growth (%)-+34.38%+139.53%+38.35%+75.79%+22.55%+101.47%+10.27%+14.62%-2.98%+82.67%+56.64%+28.46%+42.48%+16.52%+12.60%-61.22%-53.95%+757.35%+7.38%+56.57%+18.21%+29.19%+6.83%+7.75%+7.04%+9.23%+25.70%+39.97%+10.93%+6.36%+7.21%+9.61%+6.88%-6.49%-18.32%-7.36%-3.32%-1.62%+1.39%
Cost of Revenue23.30M21.00M21.10M25.20M35.40M43.30M2.20M5.50M9.95M10.50M28.52M50.19M74.51M111.00M125.20M136.51M1.46M284.74M554.32M373.61M274.38M335.19M401.99M382.10M400.26M466.78M545.49M857.70M1.17B1.24B1.43B1.63B1.82B1.96B1.81B2.11B2.28B2.53B2.31B2.90B
Gross Profit-16.90M-12.40M-500.00K3.30M14.70M18.10M121.50M130.90M146.40M141.19M248.56M383.86M483.08M683.43M800.47M905.80M402.76M-98.61M1.04B1.34B2.41B2.84B3.70B4.00B4.32B4.58B4.97B6.07B8.53B9.52B10.02B10.64B11.64B12.42B11.64B8.87B7.90B7.30B7.37B6.91B
Gross Margin-264.06%-144.19%-2.43%11.58%29.34%29.48%98.22%95.97%93.64%93.08%89.71%88.44%86.64%86.03%86.47%86.90%99.64%-52.98%65.26%78.20%89.77%89.43%90.19%91.27%91.51%90.75%90.11%87.63%87.93%88.48%87.48%86.72%86.50%86.40%86.57%80.79%77.61%74.24%76.12%70.47%
Operating Expense12.20M11.80M11.40M12.30M13.90M19.40M92.90M109.20M148.30M133.74M207.74M234.89M292.44M367.18M472.11M545.60M188.89M771.06M998.08M1.10B1.97B2.06B2.48B2.70B3.07B2.86B3.13B3.56B4.56B4.63B4.86B5.30B5.75B5.38B7.05B6.08B5.01B5.20B4.88B5.04B
Operating Income-29.10M-24.20M-11.90M-9.00M800.00K-1.30M28.60M21.70M-1.91M7.45M40.83M148.97M190.64M316.25M328.36M360.20M213.88M-869.67M43.42M236.04M440.02M779.77M1.21B1.30B1.25B1.72B1.84B2.52B3.97B4.89B5.15B5.35B5.89B7.04B4.59B2.79B2.89B2.10B2.49B1.88B
Operating Margin-454.69%-281.40%-57.77%-31.58%1.60%-2.12%23.12%15.91%-1.22%4.91%14.73%34.32%34.19%39.81%35.47%34.56%52.91%-467.23%2.72%13.77%16.40%24.59%29.62%29.59%26.48%34.16%33.34%36.29%40.94%45.44%45.00%43.55%43.77%48.98%34.16%25.42%28.40%21.32%25.74%19.14%
EBITDA-25.00M-20.40M-8.80M-5.70M4.60M3.80M35.70M28.40M6.15M18.36M56.09M168.26M215.23M347.35M530.45M430.47M257.75M-804.13M522.43M668.05M868.93M1.33B1.67B1.80B1.62B2.10B2.20B3.02B4.60B5.62B6.39B6.61B7.01B7.74B5.11B3.92B3.54B2.38B3.00B2.95B
EBITDA Margin-390.63%-237.21%-42.72%-20.00%9.18%6.19%28.86%20.82%3.93%12.10%20.24%38.77%38.60%43.72%57.30%41.30%63.76%-432.02%32.74%38.98%32.39%41.98%40.76%41.04%34.39%41.66%39.97%43.59%47.46%52.17%55.83%53.84%52.14%53.83%38.00%35.73%34.77%24.17%30.96%30.02%
Net Income-28.20M-22.60M-1.20M3.20M7.70M7.20M38.30M32.40M-4.90M5.66M40.53M89.17M138.70M220.45M333.58M272.68M148.09M-875.10M25.09M160.71M217.51M638.17M783.17M970.13M1.01B1.23B1.38B1.86B2.93B3.55B3.70B2.54B4.43B5.89B4.00B1.56B3.05B1.16B1.63B1.29B
Net Income Margin-440.63%-262.79%-5.83%11.23%15.37%11.73%30.96%23.75%-3.13%3.73%14.63%20.54%24.87%27.75%36.04%26.16%36.64%-470.14%1.57%9.38%8.11%20.12%19.11%22.16%21.31%24.45%25.02%26.86%30.25%32.95%32.34%20.69%32.93%40.96%29.76%14.17%29.95%11.81%16.87%13.18%
R&D--------91.21M87.45M132.38M145.50M177.23M221.15M302.84M314.56M100.87M1.06B685.87M747.67M718.39M925.16M1.07B1.28B1.25B1.22B1.38B1.46B1.89B2.01B1.97B2.37B2.71B2.77B4.53B3.40B2.60B2.70B2.49B1.95B
R&D as % of Total Revenue--------58.34%57.65%47.78%33.52%31.78%27.84%32.72%30.18%24.95%567.51%42.98%43.63%26.78%29.17%26.16%29.31%26.47%24.16%25.00%21.00%19.51%18.70%17.24%19.34%20.14%19.27%33.70%30.97%25.53%27.48%25.72%19.92%
Interest Expense000000000000004.31M3.95M3.55M15.18M18.90M9.65M871.00K40.50M52.00M35.80M36.10M33.00M36.50M31.90M29.50M95.50M260.00M250.80M200.60M187.40M222.50M253.60M246.60M246.90M250.30M246.00M
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.47%0.38%0.88%8.16%1.18%0.56%0.03%1.28%1.27%0.82%0.77%0.65%0.66%0.46%0.30%0.89%2.27%2.04%1.49%1.30%1.65%2.31%2.42%2.51%2.59%2.51%

Balance Sheet

Currency: USD1986-12-311987-12-311988-12-311989-12-311990-12-311991-12-311992-12-311993-12-311994-12-311995-12-311996-12-311997-12-311998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets100.90M80.70M80.90M145.20M158.50M253.10M311.20M357.00M377.86M469.20M634.57M813.83M924.72M1.28B1.43B1.72B2.01B9.50B9.17B8.37B8.55B8.63B8.48B8.55B8.09B9.05B10.13B11.86B14.32B19.50B22.88B23.65B25.29B27.23B24.62B23.88B24.55B26.84B28.05B29.44B
Total Liabilities11.60M12.80M12.90M6.00M12.80M14.10M26.20M31.80M47.93M86.22M150.20M277.53M206.10M298.44M325.45M372.21M411.57M2.45B2.34B1.46B1.40B3.09B2.67B2.29B2.64B2.62B3.17B3.24B3.50B10.13B10.75B11.05B12.26B13.90B13.93B12.92B11.17B12.05B11.33B11.18B
Total Equity89.30M67.90M68.00M139.20M145.70M239.00M285.00M325.20M329.93M382.98M484.37M536.29M718.61M979.53M1.11B1.35B1.60B7.05B6.83B6.91B7.15B5.53B5.81B6.22B5.40B6.43B6.96B8.62B10.81B9.37B12.13B12.60B13.04B13.34B10.70B10.90B13.40B14.80B16.72B18.26B
Cash70.50M54.40M54.30M33.20M12.60M56.60M85.90M74.50M54.68M45.77M62.03M70.36M25.45M56.92M48.74M54.04M45.11M314.85M209.45M568.17M661.38M659.66M622.38M581.89M759.60M514.54M570.72M602.56M1.20B1.31B2.33B1.57B1.22B2.91B1.33B2.26B3.42B1.05B2.38B3.01B
Total Debt4.40M5.20M4.80M------34.49M66.27M91.55M80.33M113.06M109.32M82.16M42.30M887.27M850.31M43.44M96.69M1.56B1.11B1.10B1.20B1.06B1.14B595.93M585.20M6.53B6.52B5.94B5.94B6.37B7.83B7.60B6.61B7.34B6.63B6.95B
Net Debt-66.10M-49.20M-49.50M-33.20M-12.60M-56.60M-85.90M-74.50M-54.68M-11.28M4.24M21.19M54.88M56.14M60.58M28.12M-2.81M572.42M640.86M-524.72M-564.68M903.32M490.71M518.08M443.93M549.56M570.05M-6.63M-621.50M5.21B4.19B4.36B4.71B3.45B6.50B5.34B3.19B6.29B4.26B3.94B

Cash Flow

Currency: USD1989-12-311990-12-311991-12-311992-12-311993-12-311994-12-311995-12-311996-12-311997-12-311998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-7.50M10.70M5.90M43.10M47.60M34.89M9.45M46.54M97.63M167.84M272.29M365.94M316.36M267.08M219.21M727.99M889.50M841.27M1.02B1.56B1.07B1.62B1.73B1.88B2.35B2.94B3.72B4.52B4.55B6.19B7.08B4.23B3.64B1.38B1.55B2.88B2.20B
Investing Cash Flow-50.90M-29.50M-48.30M-23.90M-66.70M-70.30M-92.31M-82.05M-155.20M-158.68M-210.08M-105.00M-252.91M-289.51M-278.93M-382.43M417.74M-599.77M-286.57M-365.87M-395.03M345.32M-1.65B-950.34M-1.60B-1.54B-4.55B-2.48B-2.96B-2.05B470.50M-608.60M-563.70M1.59B-4.09B-799.20M-1.37B
Financing Cash Flow64.50M-1.80M86.50M10.00M7.80M15.54M73.95M51.77M65.90M-54.08M-30.73M-269.14M-58.16M14.26M51.19M-450.96M-948.52M-148.41M-735.22M-1.24B-724.15M-1.78B-319.86M-877.48M-716.53M-755.87M986.40M-987.80M-2.38B-4.47B-5.86B-5.27B-2.09B-1.76B137.00M-683.50M-301.90M
Capital Expenditure3.10M11.10M8.40M9.40M10.80M43.67M50.31M65.64M35.55M33.61M86.33M199.12M195.53M165.90M301.25M369.76M318.38M198.31M284.11M275.95M165.65M173.06M252.18M254.55M3.51B287.80M643.00M616.10M867.40M770.60M514.50M551.80M294.90M240.30M311.40M359.80M153.80M
Free Cash Flow-10.60M-400.00K-2.50M33.70M36.80M-8.78M-40.86M-19.10M62.08M134.23M185.96M166.82M120.82M13.32M-82.03M358.22M571.13M642.96M736.53M1.29B909.25M1.45B1.48B1.63B-1.16B2.63B3.07B3.86B3.68B5.30B6.56B3.68B3.35B1.14B1.24B2.52B2.05B
Dividends Paid2.70M5.90M2.90M-----29.36M---743.00K---10.50M-1.51B986.98M4.36M11.78M27.06M67.43B66.70B54.83B5.93B0302.70M36.40M-4.60M700.00K----
FCF to OCF141.33%-3.74%-42.37%78.19%77.31%-25.18%-432.43%-41.03%63.59%79.97%68.30%45.59%38.19%4.99%-37.42%49.21%64.21%76.43%72.16%82.36%84.59%89.35%85.40%86.46%-49.63%89.26%82.70%85.34%80.94%85.68%92.73%86.95%91.90%82.64%79.87%87.49%93.02%
Dividend Paid to FCF-25.47%-1475.00%-116.00%-----47.30%---0.61%---1.84%-205.41%76.60%0.48%0.81%1.83%4148.37%-5730.90%2087.97%192.98%0.00%8.22%0.69%-0.13%0.02%----

Earnings

Report DateOct 24, 1995Feb 14, 1996May 2, 1996Jul 25, 1996Oct 30, 1996Feb 21, 1997May 8, 1997Aug 4, 1997Nov 11, 1997Feb 5, 1998Apr 20, 1998Jul 20, 1998Oct 20, 1998Feb 9, 1999Apr 20, 1999Jul 22, 1999Oct 18, 1999Feb 2, 2000Apr 20, 2000Jul 18, 2000Oct 16, 2000Jan 29, 2001Apr 19, 2001Jul 19, 2001Oct 18, 2001Jan 29, 2002Apr 18, 2002Jul 17, 2002Oct 16, 2002Jan 30, 2003Apr 15, 2003Jul 17, 2003Oct 14, 2003Mar 2, 2004Apr 30, 2004Jul 28, 2004Oct 27, 2004Feb 7, 2005Apr 27, 2005Jul 26, 2005Oct 26, 2005Feb 15, 2006Apr 26, 2006Jul 26, 2006Oct 31, 2006Feb 15, 2007May 2, 2007Jul 24, 2007Oct 23, 2007Feb 6, 2008Apr 23, 2008Jul 22, 2008Oct 21, 2008Feb 6, 2009Apr 16, 2009Jul 16, 2009Oct 20, 2009Feb 9, 2010Apr 20, 2010Jul 20, 2010Oct 26, 2010Feb 1, 2011Apr 21, 2011Jul 26, 2011Oct 28, 2011Jan 31, 2012May 1, 2012Jul 24, 2012Oct 25, 2012Jan 28, 2013Apr 25, 2013Jul 25, 2013Oct 28, 2013Jan 29, 2014Apr 23, 2014Jul 23, 2014Oct 22, 2014Jan 29, 2015Apr 24, 2015Jul 24, 2015Oct 21, 2015Jan 27, 2016Apr 21, 2016Jul 21, 2016Oct 26, 2016Jan 26, 2017Apr 25, 2017Jul 25, 2017Oct 24, 2017Jan 25, 2018Apr 24, 2018Jul 24, 2018Oct 23, 2018Jan 29, 2019Apr 24, 2019Jul 23, 2019Oct 22, 2019Jan 30, 2020Apr 22, 2020Jul 22, 2020Oct 21, 2020Feb 3, 2021Apr 22, 2021Jul 22, 2021Oct 20, 2021Feb 3, 2022May 3, 2022Jul 20, 2022Oct 25, 2022Feb 15, 2023Apr 25, 2023Jul 25, 2023Nov 8, 2023Feb 13, 2024Apr 24, 2024Aug 1, 2024Oct 30, 2024Feb 12, 2025May 1, 2025Jul 31, 2025Oct 30, 2025Feb 6, 2026Apr 29, 2026Jul 29, 2026Oct 28, 2026Oct 29, 2026
EPS Estimate-0.05-0.03-0.06-0.04-0.05-0.02-0.05-0.07-0.060.050.010.06-0.010.040.030.130.070.070.020.080.100.110.120.150.150.170.170.200.210.260.240.240.260.310.340.320.350.360.370.360.430.470.480.480.470.550.610.630.640.810.790.850.890.921.000.731.041.051.131.121.221.221.411.331.531.491.481.571.601.461.631.952.112.272.552.843.463.773.904.093.814.084.474.694.974.964.974.375.725.455.945.146.766.726.967.538.278.087.698.008.054.804.944.604.103.374.364.074.133.483.283.763.983.183.464.033.793.362.953.883.881.622.893.042.062.10
EPS Actual-0.050.020.02-0.04-0.040.01-0.02-0.04-0.080.060.030.090.020.050.040.130.070.050.020.090.100.120.120.150.160.160.170.200.220.260.240.240.260.240.400.340.370.340.300.430.360.480.550.570.570.530.590.700.580.890.830.910.980.931.050.751.121.201.081.311.351.421.431.361.611.511.401.821.911.401.972.302.352.342.473.493.804.093.824.224.484.504.795.215.195.045.205.046.315.266.055.807.406.996.989.159.178.349.1410.268.844.585.345.684.773.393.625.254.774.053.404.024.363.303.675.284.083.443.025.474.811.993.573.602.62-
Surprise0.00%166.67%133.33%0.00%20.00%150.00%60.00%42.86%-33.33%20.00%200.00%50.00%300.00%25.00%33.33%0.00%0.00%-28.57%0.00%12.50%0.00%9.09%0.00%0.00%6.67%-5.88%0.00%0.00%4.76%0.00%0.00%0.00%0.00%-22.58%17.65%6.25%5.71%-5.56%-18.92%19.44%-16.28%2.13%14.58%18.75%21.28%-3.64%-3.28%11.11%-9.38%9.88%5.06%7.06%10.11%1.09%5.00%2.74%7.69%14.29%-4.42%16.96%10.66%16.39%1.42%2.26%5.23%1.34%-5.41%15.92%19.38%-4.11%20.86%17.95%11.37%3.08%-3.14%22.89%9.83%8.49%-2.05%3.18%17.59%10.29%7.16%11.09%4.43%1.61%4.63%15.33%10.31%-3.49%1.85%12.84%9.47%4.02%0.29%21.51%10.88%3.22%18.86%28.25%9.81%-4.58%8.10%23.48%16.34%0.59%-16.97%28.99%15.50%16.38%3.66%6.91%9.55%3.77%6.07%31.02%7.65%2.38%2.37%40.98%23.97%22.84%23.53%18.42%27.18%-
Timing------Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-----------After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hours-Pre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-Pre-marketPre-market-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap36.71B
Enterprise Value43.21B
Trailing P/E107.51
Forward P/E16.08
PEG Ratio3.38
Price / Sales3.57
Price / Book1.94
EPS2.31
Book Value128.03
Revenue (TTM)10.30B
Gross Profit (TTM)7.80B
EBITDA3.30B
Profit Margin3.38%
Operating Margin24.12%
Return on Equity1.87%
Return on Assets4.94%
Shares Outstanding147.82M
Shares Float147.29M
Beta0.09
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 36 analystsTarget 266.39
  • Strong Buy
    21
  • Buy
    4
  • Hold
    10
  • Strong Sell
    1

Ownership Breakdown

Institutions
100.07%
Insiders
0.19%
Retail / Other
0.00%

Top Institutional Holders

  • FMR Inc
    18.22M12.32%
  • BlackRock Inc
    15.99M10.81%
  • PRIMECAP Management Company
    15.15M10.25%
  • Vanguard Capital Management, LLC
    9.65M6.53%
  • State Street Corp
    7.34M4.97%
  • Vanguard Portfolio Management, LLC
    6.60M4.47%
  • Geode Capital Management, LLC
    4.45M3.01%
  • Wellington Management Company LLP
    3.12M2.11%
  • NORGES BANK
    2.58M1.75%
  • Morgan Stanley - Brokerage Accounts
    2.41M1.63%
  • AQR Capital Management LLC
    1.94M1.31%

Top Fund Holders

  • Vanguard PRIMECAP Inv
    8.36M5.66%
  • Fidelity Contrafund
    5.23M3.54%
  • Vanguard MStar Total Stk Mkt Idx Invest
    4.68M3.17%
  • Vanguard 500 Index Investor
    3.88M2.63%
  • Vanguard MStar Mid Cap Index Instl
    3.16M2.14%
  • Vanguard Health Care Inv
    2.75M1.86%
  • Vanguard Capital Opportunity Inv
    2.62M1.78%
  • Fidelity Canadian Large Cp Mlt Ast Bs O
    2.31M1.56%
  • iShares Core S&P 500 ETF
    1.97M1.33%

Stock Splits

  • Jan 18, 20013:1
  • Dec 21, 19992:1